Leerink Partnrs Issues Pessimistic Forecast for BMY Earnings

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Equities researchers at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a report released on Wednesday, July 9th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will post earnings per share of $1.09 for the quarter, down from their prior forecast of $1.69. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share. Leerink Partnrs also issued estimates for Bristol Myers Squibb's FY2025 earnings at $6.20 EPS and FY2027 earnings at $6.10 EPS.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The firm's quarterly revenue was down 5.6% on a year-over-year basis. During the same quarter last year, the business posted ($4.40) EPS.

A number of other equities analysts have also weighed in on BMY. The Goldman Sachs Group reiterated a "neutral" rating and set a $55.00 price objective (down previously from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Piper Sandler assumed coverage on Bristol Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective for the company. Argus upgraded Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Morgan Stanley reduced their price objective on Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating for the company in a research note on Thursday. Finally, UBS Group reduced their price objective on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $57.69.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY traded down $1.61 during trading on Friday, reaching $46.91. 13,670,701 shares of the company traded hands, compared to its average volume of 12,830,370. The firm's fifty day simple moving average is $47.51 and its 200 day simple moving average is $53.22. The stock has a market cap of $95.47 billion, a P/E ratio of 17.57, a PEG ratio of 2.38 and a beta of 0.36. Bristol Myers Squibb has a 12-month low of $39.93 and a 12-month high of $63.33. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.29%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is 92.88%.

Insider Transactions at Bristol Myers Squibb

In other news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction that occurred on Friday, April 25th. The shares were bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president owned 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.07% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Pinney & Scofield Inc. acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth approximately $25,000. Park Square Financial Group LLC acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth approximately $26,000. Global Wealth Strategies & Associates boosted its holdings in shares of Bristol Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 275 shares during the last quarter. Transce3nd LLC acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth approximately $28,000. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Bristol Myers Squibb during the 1st quarter worth approximately $31,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.